RVL Pharmaceuticals plc financial data

Symbol
RVLPQ on OTC
Location
400 Crossing Boulevard, Bridgewater, NJ
State of incorporation
Ireland
Fiscal year end
December 31
Former names
Osmotica Pharmaceuticals plc (to 1/18/2022), Osmotica Pharmaceuticals Ltd (to 8/22/2018)
Latest financial report
10-Q - Q2 2023 - Aug 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 152 % -4.81%
Quick Ratio 2.36 % -11.3%
Debt-to-equity 173 % +70.1%
Return On Equity -155 % -78.1%
Return On Assets -56.8 % -31.6%
Operating Margin -192 % +4.05%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99.5M shares +0.39%
Common Stock, Shares, Outstanding 99.4M shares +18.9%
Entity Public Float 44.9M USD -27%
Common Stock, Value, Issued 994K USD +18.9%
Weighted Average Number of Shares Outstanding, Basic 99.4M shares +18.9%
Weighted Average Number of Shares Outstanding, Diluted 99.4M shares +18.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 36.9M USD +5.64%
Research and Development Expense 3.1M USD -34.2%
Operating Income (Loss) -70.8M USD -1.36%
Nonoperating Income (Expense) 6.95M USD +39.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -68.5M USD -4.47%
Net Income (Loss) Attributable to Parent -68.3M USD -20.8%
Earnings Per Share, Basic -0.72 USD/shares +4%
Earnings Per Share, Diluted -0.72 USD/shares +4%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 1M USD
Inventory, Net 1.36M USD +157%
Assets, Current 25.8M USD -35.9%
Operating Lease, Right-of-Use Asset 365K USD -58.1%
Intangible Assets, Net (Excluding Goodwill) 13.9M USD -48.9%
Goodwill 55.8M USD 0%
Assets 85.4M USD -31.6%
Accrued Liabilities, Current 7.86M USD -34.2%
Liabilities, Current 68.4M USD +269%
Contract with Customer, Liability, Noncurrent 1.2M USD +500%
Accrued Income Taxes, Noncurrent 71K USD +5.97%
Deferred Income Tax Liabilities, Net 25K USD -85.6%
Operating Lease, Liability, Noncurrent 180K USD -48.4%
Liabilities 69.1M USD +4.16%
Retained Earnings (Accumulated Deficit) -605M USD -12.7%
Stockholders' Equity Attributable to Parent 16.3M USD -72.1%
Liabilities and Equity 85.4M USD -31.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.82M USD +56.2%
Net Cash Provided by (Used in) Financing Activities -4.86M USD -481%
Net Cash Provided by (Used in) Investing Activities -1.23M USD -12350%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 99.4M shares +18.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.2M USD -30.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.54M USD +211%
Deferred Tax Assets, Valuation Allowance 64.9M USD +22.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure -85.5%
Operating Lease, Liability 529K USD -63%
Payments to Acquire Property, Plant, and Equipment 1.3M USD +4730%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -68.3M USD -25.8%
Lessee, Operating Lease, Liability, to be Paid 538K USD -63.6%
Operating Lease, Liability, Current 197K USD -64.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 93K USD -81.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 445K USD -49.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure -24.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9K USD -81.3%
Deferred Tax Assets, Operating Loss Carryforwards 26.9M USD +27.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 179K USD +2.29%
Additional Paid in Capital 620M USD +4.36%
Preferred Stock, Shares Outstanding 0 shares
Current Federal Tax Expense (Benefit) 4.1M USD
Depreciation, Depletion and Amortization 93K USD +4.49%
Share-based Payment Arrangement, Expense 2.21M USD -68.4%
Interest Expense 1.19M USD -70.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%